Get a quote

We're excited to learn more about your project and provide you with a customized quote tailored to your needs. Please fill out the form below, and we'll get back to you as soon as possible.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recombinant Canine Tumor Necrosis Factor Receptor Superfamily Member 4 (TNFRSF4), C-His

Cat. No.AP3F23

Product TypeAnimal Proteins

Size

Product Overview

BioVenic's Recombinant Canine Tumor Necrosis Factor Receptor Superfamily Member 4 (TNFRSF4), C-His is a recombinant protein expressed from E.coli Expression System. Its predicted molecular weight is 21.8 kDa. The purity is>90% (SDS-PAGE).

Specifications

Type Recombinant Protein
Species Canine
Expression System E.coli Expression System
Purity >90% (SDS-PAGE)
Predicted Molecular Weight 21.8 kDa
Physical State Lyophilized
Formulation PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.

Target Information

TNFRSF4 is a potent costimulatory receptor primarily expressed on activated T cells. In canines, it plays a critical role in enhancing T-cell proliferation, survival, and cytokine production by activating the NF-κB pathway. Within the tumor microenvironment, TNFRSF4 signaling suppresses regulatory T cell (Treg) activity while boosting effector T-cell memory. It is a key immuno-oncology target being explored for canine biologics to reverse immune suppression and stimulate robust anti-tumor responses in various solid tumors.

Protein Canine Tumor Necrosis Factor Receptor Superfamily Member 4 (TNFRSF4)
Protein Synonym OX40; CD134; ACT35; TXGP1L; TNFRSF4
Gene ID 112647022
UniProt ID A0A8C0KEZ3

Shipping and Storage

This product is shipped with gel ice bags. Avoid repeated freezing and thawing. Store for 12 months at -20°C or -80°C.

Documents

COA

To request a Certificate of Analysis, please enter the Lot No. in the search box. Note: Certificate of Analysis not available for kits.

The product is for research use only.
Not for commercial, prophylactic, diagnostic, or therapeutic applications.

User Note

  1. Always centrifuge tubes before opening. Avoid mixing by vortexing or pipetting. Aliquote the reconstituted solution to minimise freeze-thaw cycles.
Inquiry Basket